Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Naurex
About
Naurex is a clinical-stage company developing novel therapeutics for depression and other CNS disorders.
- 11 - 50
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $25M
- Industries
- Biopharma,Biotechnology,Therapeutics
- Founded date
- Jan 1, 2008
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 3, 2014 | Series C | $80M | 2 | — | — | Detail |
| May 6, 2014 | Series C | $25M | 1 | — | — | Detail |
| Dec 17, 2012 | Series B | $38M | 2 | — | — | Detail |
| May 11, 2011 | Series A | $18M | 2 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
|
|
— | Series C |
Takeda
|
— | Series C |
